Cargando…
NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma
BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common head and neck malignancy with a high mortality rate and poor prognosis. The exploration and understanding of biomarkers will help to further improve the diagnosis and treatment of OSCC. METHODS: Tumor tissue samples from 319 OSCC pat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474866/ https://www.ncbi.nlm.nih.gov/pubmed/37663758 http://dx.doi.org/10.2147/JIR.S426277 |
_version_ | 1785100596757397504 |
---|---|
author | Yu, Xin Xu, Lijun Zhou, Yongqiang Zhou, Xiaorong Yang, Lei Zhou, Yan |
author_facet | Yu, Xin Xu, Lijun Zhou, Yongqiang Zhou, Xiaorong Yang, Lei Zhou, Yan |
author_sort | Yu, Xin |
collection | PubMed |
description | BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common head and neck malignancy with a high mortality rate and poor prognosis. The exploration and understanding of biomarkers will help to further improve the diagnosis and treatment of OSCC. METHODS: Tumor tissue samples from 319 OSCC patients were retrospectively collected, along with their clinical information. In combination with bioinformatics tools and multiplex immunohistochemistry (mIHC) analyses, we evaluated NUP62CL protein expression and its relationship to tumor-infiltrating immune cells (TIICs) and immune checkpoints in the tumor microenvironment (TME), as well as its association with clinical features and prognosis of OSCC. RESULTS: We identified high-NUP62CL expression in OSCC tissues, and high-NUP62CL protein expression was associated with large tumor size, advanced clinical stage and poor prognosis. In addition, NUP62CL protein expression was positively associated with the abundance of CD3+CD4+ T cells (P<0.01), CD3+CD8+ T cells (P<0.01), CD56+ NK cells (P<0.05), CD68+CD86+ macrophages (P<0.01) and CD68+CD163+ macrophages (P<0.01), as well as the immune checkpoints, including PD-1 (P<0.001), PD-L1 (P<0.001), and CTLA-4 (P<0.001) protein expression. CONCLUSION: In conclusion, NUP62CL could be an effective prognostic and immunological biomarker for OSCC patients. |
format | Online Article Text |
id | pubmed-10474866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-104748662023-09-03 NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma Yu, Xin Xu, Lijun Zhou, Yongqiang Zhou, Xiaorong Yang, Lei Zhou, Yan J Inflamm Res Original Research BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common head and neck malignancy with a high mortality rate and poor prognosis. The exploration and understanding of biomarkers will help to further improve the diagnosis and treatment of OSCC. METHODS: Tumor tissue samples from 319 OSCC patients were retrospectively collected, along with their clinical information. In combination with bioinformatics tools and multiplex immunohistochemistry (mIHC) analyses, we evaluated NUP62CL protein expression and its relationship to tumor-infiltrating immune cells (TIICs) and immune checkpoints in the tumor microenvironment (TME), as well as its association with clinical features and prognosis of OSCC. RESULTS: We identified high-NUP62CL expression in OSCC tissues, and high-NUP62CL protein expression was associated with large tumor size, advanced clinical stage and poor prognosis. In addition, NUP62CL protein expression was positively associated with the abundance of CD3+CD4+ T cells (P<0.01), CD3+CD8+ T cells (P<0.01), CD56+ NK cells (P<0.05), CD68+CD86+ macrophages (P<0.01) and CD68+CD163+ macrophages (P<0.01), as well as the immune checkpoints, including PD-1 (P<0.001), PD-L1 (P<0.001), and CTLA-4 (P<0.001) protein expression. CONCLUSION: In conclusion, NUP62CL could be an effective prognostic and immunological biomarker for OSCC patients. Dove 2023-08-29 /pmc/articles/PMC10474866/ /pubmed/37663758 http://dx.doi.org/10.2147/JIR.S426277 Text en © 2023 Yu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yu, Xin Xu, Lijun Zhou, Yongqiang Zhou, Xiaorong Yang, Lei Zhou, Yan NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma |
title | NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma |
title_full | NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma |
title_fullStr | NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma |
title_full_unstemmed | NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma |
title_short | NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma |
title_sort | nup62cl as an immunological and prognostic biomarker of oral squamous cell carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474866/ https://www.ncbi.nlm.nih.gov/pubmed/37663758 http://dx.doi.org/10.2147/JIR.S426277 |
work_keys_str_mv | AT yuxin nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma AT xulijun nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma AT zhouyongqiang nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma AT zhouxiaorong nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma AT yanglei nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma AT zhouyan nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma |